Physician profile
Vanderbilt W Robison
NPI 1972950491
$1,037.16
in general payments reported to CMS, 2019-2025
11 companies · $10.13 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $12.98 · 2021: $33.57 · 2022: $21.83 · 2023: $504 · 2024: $270 · 2025: $10.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $279.48 | 2023-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $191.78 | 2019-2024 | Ingrezza |
| Lundbeck LLC | $139.24 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $124.03 | 2023 | Quviviq |
| Boston Scientific Corporation | $115.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $85.06 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $33.33 | 2023 | Trintellix |
| Bausch Health US, LLC | $27.55 | 2020-2023 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $16.63 | 2023 | Sertraline Hcl, Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $14.16 | 2024 | Rexulti |
| Tms Neurohealth Centers INC. | $10.13 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanderbilt Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.